Renal Cell Carcinoma

In the phase 3 CLEAR study, lenvatinib combined with pembrolizumab continued to elicit deep and durable tumor response among patients with advanced clear cell renal cell carcinoma.

Belzutifan led to improved progression-free survival and objective response rate compared to everolimus for patients with advanced clear cell renal cell carcinoma, according to study findings.

“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.

The phase 3 CheckMate -67T trial found that a subcutaneous formulation of nivolumab met its co-primary pharmacokinetic end points compared with the intravenous formulation in clear cell renal cell carcinoma.

The tool shows promise to predict a patient’s response to dovitinib to better inform treatment options for patients with renal cell carcinoma and other solid tumors.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel George, MD, discussed the CheckMate 9ER trial in terms of bone, liver, and lung metastases and other subgroups in patients with advanced clear cell renal cell carcinoma.

In the first article of a 2-part series, Benjamin Garmezy, MD, discusses risk stratification and combination options in the metastatic clear cell renal cell carcinoma setting.

Results from the EVEREST study do not support the adjuvant use of everolimus for patients with renal cell carcinoma following surgery.

Combination therapies for patients with advanced renal cell carcinoma provides clinicians with new treatment avenues for their patients. To assess which path to go down, Tian Zhang, MD, MHS, and Randy F. Sweis, MD, led virtual discussions on evaluating patients’ risk criteria to determine their proper treatment.

In an interview, Chung-Han Lee, MD, PhD, discussed the challenges, studies, and outcomes previously observed when studying adjuvant treatments for patients with renal cell carcinoma.

Chung-Han Lee, MD, PhD, discusses the types of research that are needed to push forward the development of adjuvant treatments for patients with renal cell carcinoma.

Samer A. Srour, MB, ChB, MS, discusses the design of ALLO-316, an agent investigated in the phase 2 TRAVERSE trial for patients with renal cell carcinoma.

A medical oncologist reviews recent data updates from the 2023 ASCO Annual Meeting for non–clear cell renal cell carcinoma.

Clinical insights from a leader in kidney cancer research on the differences between clear cell and non–clear cell renal cell carcinoma.

A speedy review of an approval application for belzutifan has been undertaken by the FDA.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ulka Vaishampayan, MD, discussed the TIVO-3 study of tivozanib for patients with recurrent advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandy Liu, MD, discussed the potency of immunotherapy and tyrosine kinase inhibitor combinations for patients with metastatic renal cell carcinoma.

Robert J. Motzer, MD, discusses unmet needs and looks to the future of treatment for patients with clear cell renal cell carcinoma.

Expert perspectives on how adverse events differ among the available clear cell renal cell carcinoma treatment options.

In the second article of a 2-part series, Sumanta K. Pal, MD, leads a discussion on what therapies physicians consider in the later-line settings for treatment of patients with advanced renal cell carcinoma.

A key opinion leader in the field of renal cell carcinoma offers clinical insight on treatment sequencing strategies.

A comprehensive review of second-line treatment options for patients with clear cell renal cell carcinoma.

In the second article of a 2-part series, Rana McKay, MD, discussed follow-up analyses of the phase 3 CheckMate 9ER trial that showed the benefit of nivolumab plus cabozantinib vs sunitinib for patients with advanced renal cell carcinoma.

Eric A. Singer, MD, MS, discusses future developments that could improve the utilization of adjuvant therapy for high-risk renal cell carcinoma.

Robert J. Motzer, MD, provides insights on factors that influence treatment decisions for patients with clear cell renal cell carcinoma.